Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report released on Monday, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on LXRX. Needham & Company LLC restated a hold rating on shares of Lexicon Pharmaceuticals in a research report on Friday, May 3rd. StockNews.com upgraded Lexicon Pharmaceuticals to a sell rating in a research report on Thursday, June 6th. SVB Leerink started coverage on Lexicon Pharmaceuticals in a report on Tuesday, April 30th. They issued an outperform rating and a $5.00 target price for the company. Finally, Leerink Partnrs reiterated an outperform rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Hold and a consensus price target of $6.67.

Lexicon Pharmaceuticals Price Performance

Lexicon Pharmaceuticals stock opened at $1.68 on Monday. The company has a current ratio of 15.58, a quick ratio of 15.56 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $413.68 million, a PE ratio of -2.02 and a beta of 1.38. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.73. The stock has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $1.91.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The firm had revenue of $1.13 million during the quarter, compared to the consensus estimate of $1.17 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 108.54%. Analysts expect that Lexicon Pharmaceuticals will post -0.7 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank boosted its position in shares of Lexicon Pharmaceuticals by 4.4% during the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,300 shares during the last quarter. KWB Wealth purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $62,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Lexicon Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 22,043 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Lexicon Pharmaceuticals by 22.0% during the fourth quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 5,813 shares during the last quarter. Finally, Principal Securities Inc. purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.